Biopharmaceutical executives must consider how outsourcing fits into their development and production strategy, as well as how to select the best CDMO partner for their business. Here’s a step-by-step guide to help make those decisions.
Biopharmaceutical companies take on a lot of risk developing new large molecule drugs. With more complex molecules in development, changing capacity needs, uncertain forecasts, and increased competition, the market demands flexibility and innovative approaches to address today's new challenges.
To forecast demand, a company must factor in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market, and a host of other variables. Variations in any one of those factors can lead to drastically different demand scenarios. Read more to learn how to manage this uncertainty.
Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for cash-strapped companies whose hopes for success hinge upon just one or two molecules. Whether biopharmaceutical companies have one candidate or 100, the directive is clear: moving quickly into FIH testing is essential. But, how?